🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TAIC FOLFOX for Locally Advanced G/GEJA

RecruitingPhase 2Ages 18 Years - anyAllGuang'anmen Hospital of China Academy of Chinese …
NCT07655024 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Gastric cancer is the fifth most common malignancy worldwide in terms of both incidence and mortality. The majority of cases are diagnosed at advanced stage-often presenting with severe complications such as malignant stricture, obstruction, bleeding, and cancer-related malnutrition-which impinge on quality of life and survival outcomes. For patients with unresectable or metastatic gastric cancer and gastroesophageal junction adenocarcinoma (G/GEJA), first-line systemic therapy remains predominantly platinum- and fluoropyrimidine-based combination chemotherapy, and targeted agents or immunotherapy can be added based on the expression of biomarkers. Under this standard approach, the median overall survival (mOS) for localized unresectable G/GEJA is approximately 14-20 months. For metastatic G/GEJA, the prognosis remains poor with an mOS of less than 1 year, despite the proven efficacy of

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Pathologically diagnosed with G/GEJA * Confirmed by the surgeon as initially unresectable advanced G/GEJC * Contraindicated to surgery due to frailty or comorbidities * Expected survival period ≥ 3 months Exclusion Criteria: * Primary malignant tumors * Gastrointestinal obstruction caused by lesions in the distal stomach, duodenum, pancreas or other organs * Acute infection, severe liver or kidney dysfunction or coagulation disorder * Allergic to the drugs or with mental disorders
💊

What it tests

  • TAIC
  • FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
📍

Where

1 site
Department of General Surgery, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St, West-city District, Beijing, China
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy